Science sourced worldwide
LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates
Global Clinical Trials Status
Cardiovascular
Phase 1
Phase 2
Phase 3/Pivotal
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
Precision Diastolic Disease (HFpEF)
Oncology
Phase 1
Phase 2
Phase 3/Pivotal
First-line Cholangiocarcinoma (1LCCA)
Second-line Cholangiocarcinoma (2LCCA)*
Gastric Cancer and Other FGFR-Driven Tumors
*LianBio will pursue approval in ex-China LianBio Territories via CPP (i.e. clinical trial waivers with regulatory submission post US FDA approval).
Head and Neck Cancer
Solid tumor IO combinations
SHP2 Inhibitor for RTK Cancers
Ophthalmology
Phase 1
Phase 2
Phase 3/Pivotal
Demodex blepharitis
Meibomian gland disease
Inflammatory Disease
Phase 1
Phase 2
Phase 3/Pivotal
Ulcerative Colitis
Crohn’s Disease
Ulcerative Colitis
Crohn’s Disease
Chronic Rhinosinusitis (CRS)
Respiratory
Phase 1
Phase 2
Phase 3/Pivotal
Respiratory Syncytial Virus (RSV)
